Journal for ImmunoTherapy of Cancer – Page 69

Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081

15 de July de 2025 by

Background
For unresectable stage III non-small-cell lung cancer (NSCLC), the optimal duration and regimen of consolidation immunotherapy following chemoradiation is unknown. Despite improved outcomes with 12 months of durvalumab, which has become the…

Anti-galectin-9 therapy synergizes with EGFR inhibition to reprogram the tumor microenvironment and overcome immune evasion

15 de July de 2025 by

Background
Despite the remarkable clinical outcomes of epidermal growth factor receptor (EGFR)-targeted therapies in patients with lung cancer, therapeutic resistance eventually develops. This study elucidates the role of galectin-9 (Gal-9), a TIM-3 i…

Characteristics of cancer mycobiome in patients with acral melanoma

15 de July de 2025 by Huang, R., Su, X., Wang, J., Sun, Q., Kang, D., Li, L., Wu, Y., Zhao, L., Xie, Z., Zou, Z.

Background
Intratumoral fungi have recently been implicated in cancer initiation and progression, with potential as biomarkers for predicting clinical outcomes and treatment response in patients with cancer. However, their role in acral melanoma (AM) …

Tumor organoids in immunotherapy: from disease modeling to translational research

15 de July de 2025 by Si, Q., Tao, S., Wu, J., Ma, J., Li, Z., Feng, X., Song, J., Kong, T., Zhou, Z.

Tumor organoids have emerged as transformative tools in cancer research, enabling the study of tumor biology and immunology in a physiologically relevant, three-dimensional in vitro environment. Derived from patient tumor samples, these self-organizin…

Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer

15 de July de 2025 by

Background
Napsin A is normally expressed in human lung pneumocytes and is a highly expressed cancer antigen in lung adenocarcinoma. We examined whether T cells specific for Napsin A may play a role in immune checkpoint inhibitor (ICI)-mediated respon…

Engineered IL-18 variants with half-life extension and improved stability for cancer immunotherapy

15 de July de 2025 by

Background
The pro-inflammatory cytokine, interleukin-18 (IL-18), plays an instrumental role in bolstering anti-tumor immunity. However, the therapeutic application of IL-18 has been limited due to its susceptibility to neutralization by IL-18 binding…

Review: radiotherapy-mediated B cells within the TLS influence the tumor microenvironment

15 de July de 2025 by Yang, H., Chen, K., Meng, Y., Chen, Z., Xu, Y., Zhou, D., Zhou, S., Zhang, X.

The tumor microenvironment (TME) is a diverse and intricate structure consisting of tumor cells, stromal cells, endothelial cells, and immune cells. It is characterized by the communication between tumor cells and both innate and adaptive immune cells…

ANV600 is a novel PD-1 targeted IL-2R{beta}{gamma} agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy

15 de July de 2025 by

Background
Combining interleukin-2 (IL-2) agonism with programmed cell death protein 1 (PD-1) checkpoint inhibition has shown synergistic potential in reinvigorating antitumor T cell responses. However, integrating these two mechanisms within a single…

Targeting HK3 in tumor-associated macrophages enhances antitumor immunity through augmenting antigen cross-presentation in cervical cancer

15 de July de 2025 by

Background
Tumor-associated macrophages (TAMs) are among the most prevalent cells within the tumor microenvironment (TME) of cervical cancer (CC). Although TAMs frequently exhibit an immunosuppressive phenotype, their plasticity enables them as an int…

Allogeneic cetuximab-armed gamma delta T cells using antibody-cell conjugation technology for the treatment of EGFR-expressing solid tumors

15 de July de 2025 by

Background
Targeting epidermal growth factor receptor (EGFR) has become a strategic approach in cancer therapy, using various modalities including chimeric antigen receptor (CAR)-αβT cell therapies. Despite significant advancements in autol…